Award
National Institute on Aging 1R01AG088141-01A1
Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People with Down Syndrome
Recipient
Brigham and Women's Hospital
Award Amount
$801,359.00
Ceiling
$801,359.00
Awarded
September 08, 2025
Identifier
1R01AG088141-01A1
This award funds a phase 1 clinical trial investigating the safety, tolerability, and pharmacokinetics/pharmacodynamics of NMN to prevent or reverse Alzheimer's Disease in adults with Down syndrome.
Description
A multiple ascending dose, placebo-controlled, phase 1 trial to determine the safety and tolerability, as well as pharmacokinetics and pharmacodynamics of nicotinamide mononucleotide (NMN) in adults with Down syndrome, aiming to prevent or reverse Alzheimer's Disease progression.